Kestra Investment Management LLC Buys Shares of 2,972 Eli Lilly and Company (NYSE:LLY)

Kestra Investment Management LLC acquired a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 2,972 shares of the company's stock, valued at approximately $2,633,000.

A number of other large investors have also recently bought and sold shares of the business. Chesley Taft & Associates LLC raised its stake in shares of Eli Lilly and Company by 5.4% in the 2nd quarter. Chesley Taft & Associates LLC now owns 22,553 shares of the company's stock valued at $20,419,000 after acquiring an additional 1,163 shares in the last quarter. OMNI 360 Wealth Inc. acquired a new stake in shares of Eli Lilly and Company in the second quarter worth $239,000. Long Run Wealth Advisors LLC bought a new stake in shares of Eli Lilly and Company during the 2nd quarter worth $209,000. Essex Financial Services Inc. grew its stake in Eli Lilly and Company by 5.8% in the 2nd quarter. Essex Financial Services Inc. now owns 28,183 shares of the company's stock valued at $25,517,000 after buying an additional 1,556 shares during the last quarter. Finally, Sitrin Capital Management LLC bought a new position in Eli Lilly and Company in the 2nd quarter worth $5,986,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Price Performance

LLY traded up $7.16 during midday trading on Friday, reaching $795.35. 2,206,918 shares of the company's stock were exchanged, compared to its average volume of 4,869,603. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The business has a 50-day simple moving average of $851.90 and a two-hundred day simple moving average of $870.26. The firm has a market capitalization of $755.04 billion, a price-to-earnings ratio of 85.98, a price-to-earnings-growth ratio of 3.01 and a beta of 0.43. Eli Lilly and Company has a one year low of $561.65 and a one year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. During the same quarter last year, the business earned $0.10 EPS. Eli Lilly and Company's quarterly revenue was up 20.4% compared to the same quarter last year. As a group, research analysts predict that Eli Lilly and Company will post 13.2 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 0.65%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company's payout ratio is 56.22%.

Wall Street Analyst Weigh In

A number of research firms have issued reports on LLY. Bank of America decreased their price target on shares of Eli Lilly and Company from $1,150.00 to $1,100.00 and set a "buy" rating for the company in a report on Thursday, October 31st. Barclays lowered their target price on Eli Lilly and Company from $1,025.00 to $975.00 and set an "overweight" rating on the stock in a report on Thursday, October 31st. Citigroup lifted their price target on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a "buy" rating in a research report on Friday, October 25th. Wolfe Research assumed coverage on Eli Lilly and Company in a research report on Friday, November 15th. They issued an "outperform" rating and a $1,000.00 price objective for the company. Finally, BMO Capital Markets boosted their target price on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an "outperform" rating in a research report on Friday, August 9th. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,007.94.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the transaction, the chief accounting officer now directly owns 5,480 shares in the company, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.13% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.